





Workshop on "Clinical perspectives and commercial forces on biosensor devices"

University of Bath, East Building 1.1, 16-18 September 2014

Tuesday 16 September 2014

|--|--|

Wednesday 17 September 2014: Clinical Awareness Sessions (prostate cancer) + topical lectures

Time	Item	Speaker
8:30	Registration & Coffee	
9:00	Overview of research ethics, human tissue act, Good Clinical Practice	Jenna Bowen, Cardiff University
9:30	Prostate cancer overview	Simon Evans, Royal United Hospital Bath
10:00	Prostate cancer diagnosis and risks	Jonathan McFarlane, Royal United Hospital Bath
10:30	Coffee	
10:45	Prostate cancer treatment options – surveillance and surgical	Jonathan McFarlane, Royal United Hospital Bath
11:15	Prostate cancer treatment options – radiotherapy techniques and advanced disease	Mark Beresford, Royal United Hospital Bath
11:45	The patient's experience	Miranda Benney, Royal United Hospital Bath
		Expert patient
12:15	Lunch & Poster Session	
13:15	The patient's experience	Paul Jordan, Expert patient, Prostate Cancer UK
13:40	Mock MDT meeting / Case study	All
14:10	Urinary biomarkers - the role of urinary volatile organic compounds in diagnosis of prostate cancer	Emmanuel Johnson, Bristol Urological Institute









14:40	Discussion: End-user requirements of diagnostic tests	All	
15:00	Coffee & Poster Session		
	Topical Lectures:		
16:00	Overview of Prostate Cancer Biomarkers	Guido Jenster, Erasmus University Medical Center (NL)	
16:45	Role of AMACR in prostate cancer	Matthew Lloyd, University of Bath	
17:15	From RNA to patients: novel opportunities in clinical research	Michael Ladomery, University of the West of England	
18:00	Close		
20:00	Dinner – Hall & Woodhouse		

Thursday 18 September 2014: Biosensor Commercialisation Sessions + topical lectures

Time	Item	Speaker	
8:30	Registration & Coffee		
9:00	A University Spin-Out – the pleasure and the pain	Janice Kiely, University of the West of England	
9:30	Commercialisation of Point of Care Assays	Kris Zak, KZ Bio Itd	
10:10	Commercialising biosensors and diagnostics: making the transition from the academic to the industrial setting	Paul Ko Ferrigno, Avacta Group plc	
	Commercialising biosensors and diagnostics: how companies assess an academic proposal		
11:00	Coffee		
11:15	Technology is not always enough – a lesson from glucose monitoring	Richard Guy, University of Bath	
11:45	The commercialisation of magnetic biosensors	Guido Drago, Gwent Group	
12:15	Discussion: Commercially viable biosensor devices	All	
12:45	Lunch & Poster Session		









14:00	Topical Lectures: Oligonucleotide aptamers	Tony Cass, Imperial College London
14:45	Peptide aptamers	Paul Ko Ferrigno, Avacta Life Sciences Ltd
15:45	Close	

